Derek (More Plates More Dates) TRT Public Transformation Timeline

Who Is Derek from More Plates More Dates?

Derek is the pseudonymously branded creator of More Plates More Dates (MPMD), a YouTube channel and media brand he built into the largest testosterone, performance-enhancing drug (PED), and hair-loss education platform in the English-speaking fitness space. By early 2025, the channel had surpassed 1.8 million subscribers and produced hundreds of hours of content referencing peer-reviewed endocrinology, pharmacology, and clinical trial data.

His approach is unusual in the creator economy. Where most fitness influencers discuss training splits, Derek cites primary literature. He regularly references the Endocrine Society's Clinical Practice Guideline on testosterone therapy, which defines hypogonadism as a total testosterone level below 300 ng/dL on two morning measurements, combined with symptoms [1]. That same guideline underpins most legitimate TRT prescribing decisions in the United States today.

Background Before TRT

Derek built his audience initially as a natural lifter discussing evidence-based training and supplementation. He documented his diet, blood work, and physique over several years before any TRT disclosure, giving viewers an unusual longitudinal baseline.

His early content focused heavily on hair loss. Derek has openly discussed having androgenetic alopecia and experimenting with finasteride, a 5-alpha reductase inhibitor that reduces scalp dihydrotestosterone (DHT) by approximately 70% at the standard 1 mg/day oral dose [2]. He later publicly explored dutasteride, which inhibits both type I and type II 5-alpha reductase isoenzymes and suppresses DHT by roughly 90% [3].

The Hair Loss and Hormonal Intersection

This is not a trivial detail. Finasteride and dutasteride both affect androgen signaling, and Derek documented how these compounds interacted with his broader hormonal picture. He described tracking serum DHT and noting the downstream effects on libido and mood, a clinically recognized phenomenon sometimes called post-finasteride concerns, though the FDA's pharmacovigilance database shows the incidence of persistent sexual side effects remains contested in the literature [4].

That intersection of hair-loss pharmacology and testosterone physiology became a central thread of his content, and it set the stage for his eventual TRT disclosure.

Derek's TRT Disclosure: What He Has Said Publicly

Derek confirmed on his own channel and in podcast appearances that he initiated testosterone replacement therapy. He framed the decision around lab values. He cited total testosterone levels in what he described as the low-to-mid-normal range for his age alongside symptoms including suboptimal energy and libido, which is consistent with the symptomatic criteria the Endocrine Society requires before recommending TRT [1].

He has stated clearly, in multiple public contexts, that his goal is not supraphysiologic testosterone for bodybuilding purposes. His stated target is a total testosterone level in the upper-normal physiologic range, which the Endocrine Society guideline places at roughly 300 to 1,000 ng/dL, with most clinicians aiming for 600 to 900 ng/dL for TRT patients [1].

The Protocol He Has Discussed

Derek has described using testosterone cypionate or enanthate, both long-acting esterified forms of testosterone with half-lives of approximately 7 to 8 days for cypionate and 4 to 5 days for enanthate [5]. These are the two most commonly prescribed injectable testosterone formulations in the United States, and their pharmacokinetics make twice-weekly injections the standard approach for minimizing peak-to-trough fluctuations.

He has discussed doses in what would be considered replacement range, not the supraphysiologic doses (300 to 600 mg per week) associated with bodybuilding. Standard TRT dosing guidelines from the Endocrine Society recommend 75 to 100 mg of testosterone cypionate or enanthate weekly, or 50 mg twice weekly, titrated to achieve mid-normal serum testosterone [1].

Derek has also disclosed using human chorionic gonadotropin (HCG), a luteinizing hormone (LH) analog that stimulates Leydig cell testosterone production and helps preserve testicular volume during exogenous testosterone use. The standard HCG co-administration dose in TRT contexts is 500 to 1,000 IU given two to three times per week [6].

Estradiol Management

Exogenous testosterone aromatizes to estradiol, and supraphysiologic estradiol can cause gynecomastia, water retention, and mood changes. Derek has discussed anastrozole, an aromatase inhibitor, in this context. The Endocrine Society guideline explicitly cautions against routine aromatase inhibitor use in TRT patients, recommending it only when estradiol rises into a range causing clinical symptoms, and even then at the lowest effective dose [1]. Derek has echoed this conservative stance in his content, warning against over-suppressing estradiol, which can impair bone density and libido.

The Transformation Timeline: Year by Year

Understanding Derek's physical changes requires separating what is publicly documented from what must be labeled as inference.

Pre-2018: Natural Baseline

Derek's early videos show a lean, muscular physique built over years of resistance training and tracked nutrition. His stated body weight during this period was approximately 180 to 190 lb at a height he has described as around 6 feet. No TRT or exogenous androgens were disclosed during this window. Hair thinning was visible on camera by this point, consistent with his early androgenetic alopecia.

2018 to 2020: Finasteride and Dutasteride Period

During this window, Derek was publicly experimenting with hair-loss pharmacology and tracking detailed blood work. He posted lab results showing suppressed DHT, discussed titrating finasteride doses, and later switched to dutasteride. His physique remained consistent with natural training norms. Body composition appeared to improve modestly, consistent with the training and nutrition optimization he was documenting, rather than any androgenic augmentation.

2020 to 2021: TRT Initiation (Inference Labeled)

Based on Derek's own public statements across multiple videos and podcast appearances, TRT initiation appears to have occurred in approximately 2020 to 2021. He described receiving a diagnosis of hypogonadism based on lab values and symptom criteria. The exact date has not been confirmed with a medical record; this timeline is drawn from the chronology of his content and his own on-record descriptions.

2021 to 2023: Protocol Stabilization

During this period, Derek's content shifted substantially toward bloodwork interpretation, TRT management, and long-term hormonal health. His physique remained muscular but did not display the dramatic mass gains associated with supraphysiologic androgen use. This is consistent with TRT at replacement doses, which meta-analyses show increases lean mass by approximately 1.6 kg over 12 months compared to placebo in hypogonadal men [7].

A 2023 Cochrane review of testosterone therapy in middle-aged and older men confirmed that replacement-dose TRT produces modest but statistically significant improvements in lean body mass, sexual function, and mood, without the dramatic body-composition shifts seen with performance-enhancing doses [7].

2023 to Present: Public Longevity Focus

Derek's more recent content has expanded into longevity medicine, cardiovascular risk, and hormonal optimization beyond testosterone alone. He has discussed topics including lipid management, cardiovascular markers, and the long-term safety data around exogenous testosterone. This mirrors a broader shift in the TRT conversation toward the TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, which found that testosterone replacement in middle-aged and older men with hypogonadism and cardiovascular risk factors did not increase major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months [8].

What the Clinical Evidence Says About His Approach

Derek's public protocol, as he has described it, aligns closely with evidence-based TRT principles.

Testosterone Levels and Symptom Criteria

The Endocrine Society guideline states: "We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels" [1]. Derek has cited symptom criteria alongside lab values in his disclosures, which matches this diagnostic framework.

Injectable vs. Topical Testosterone

Derek has favored injectable testosterone over topical gels. This is clinically reasonable. A 2019 analysis in the Journal of Clinical Endocrinology and Metabolism found that injectable testosterone produces more predictable serum testosterone levels compared to transdermal gels, which have high inter-individual absorption variability [5]. Twice-weekly injections of testosterone cypionate consistently achieve trough levels above 400 ng/dL in most patients, a threshold often associated with symptomatic benefit.

HCG Co-Administration

The use of HCG alongside TRT to preserve testicular function is not universally endorsed by guidelines but is supported by evidence. A study published in the Journal of Clinical Endocrinology and Metabolism (N=29) showed that 500 IU of HCG every other day maintained intratesticular testosterone concentrations at levels comparable to the pre-TRT baseline, while exogenous testosterone alone suppressed intratesticular testosterone by 94% [6].

Monitoring Frequency

Derek has emphasized regular bloodwork monitoring, including complete blood count (CBC) to track hematocrit, since testosterone therapy raises erythropoiesis and can increase hematocrit above 54%, the threshold at which the Endocrine Society recommends dose reduction or therapeutic phlebotomy [1]. He has also tracked prostate-specific antigen (PSA), which the guideline recommends monitoring at baseline, 3 to 6 months, and then annually in TRT patients [1].

Hair Loss Treatment Alongside TRT: The DHT Problem

One of the most clinically interesting aspects of Derek's public protocol is the intersection of TRT and androgenetic alopecia treatment.

Exogenous testosterone raises both serum testosterone and, through 5-alpha reductase conversion, serum and scalp DHT. For someone genetically predisposed to androgenetic alopecia, TRT can accelerate hair loss. Derek has discussed this tension extensively.

Finasteride During TRT

Using finasteride (1 mg/day) during TRT can blunt the TRT-driven DHT increase. A randomized trial published in the Journal of the American Academy of Dermatology demonstrated that finasteride 1 mg/day produced significant scalp hair regrowth compared to placebo over 12 months (P<0.001) in men with androgenetic alopecia [2]. Derek has cited similar data while also discussing the trade-offs around DHT suppression and its effects on mood and libido.

Dutasteride as an Alternative

Dutasteride 0.5 mg/day suppresses serum DHT more completely than finasteride. A 24-week double-blind trial (N=416) published in the Journal of the American Academy of Dermatology found dutasteride 0.5 mg/day produced greater increases in total hair count than finasteride 1 mg/day [3]. Derek has discussed transitioning to dutasteride and monitoring blood DHT to confirm suppression.

Why MPMD's Self-Documentation Matters Clinically

Derek's willingness to post actual blood work, discuss protocol adjustments, and cite peer-reviewed literature has made him an atypical figure in fitness media. His approach has real value for the estimated 2 to 4 million American men currently on testosterone therapy [9].

Most men who seek TRT have limited access to detailed, evidence-based explanations of what their labs mean or how their protocol should be adjusted. A 2020 survey published in JAMA Internal Medicine found that fewer than 50% of men prescribed testosterone therapy received a follow-up testosterone measurement within 12 months of initiation [9]. Derek's content, whatever its limitations as a non-clinical source, pushes viewers toward asking better questions of their prescribers.

The Endocrine Society's 2018 guideline explicitly notes that shared decision-making between patient and clinician is essential in TRT management, and that patients should understand the monitoring requirements before starting therapy [1]. Derek's detailed public protocol discussions contribute to that informed-patient framework, even if his individual experience cannot be generalized.

Interpreting His Physique Changes: Setting Realistic Expectations

One reason Derek's content resonates with a broad audience is that his physique, while clearly muscular, does not reflect the extreme mass associated with supraphysiologic androgen use. This matters for setting realistic patient expectations.

A 2022 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (19 randomized controlled trials, N=1,676) found that TRT at replacement doses increased fat-free mass by a weighted mean of 1.6 kg and decreased fat mass by 1.6 kg over 6 to 36 months, compared to placebo [7]. Those are meaningful but modest changes. They are not the 20 to 30 lb lean-mass gains sometimes attributed to TRT in fitness media.

Derek's visible physique changes across his documented timeline are consistent with this range, combined with years of resistance training and optimized nutrition. Any attribution beyond that is speculative, and he has been relatively transparent about that distinction in his content.

Key Takeaways for Men Considering TRT

A man reviewing Derek's public journey and considering TRT for himself should understand several evidence-based points.

TRT is indicated only for confirmed hypogonadism, meaning two morning total testosterone measurements below 300 ng/dL with corresponding symptoms, per the Endocrine Society [1]. Self-diagnosed "low T" without lab confirmation is not a clinical indication.

Standard TRT doses (75 to 100 mg of testosterone cypionate per week) produce physiologic testosterone levels, not supraphysiologic ones. The TRAVERSE trial showed that properly managed TRT does not increase cardiovascular event risk over 33 months in men with pre-existing cardiovascular risk factors [8].

Men with androgenetic alopecia who start TRT should discuss 5-alpha reductase inhibitors with their prescriber before initiation, since testosterone-driven DHT elevation can accelerate hair loss in genetically susceptible individuals.

Follow-up blood work at 3 months, 6 months, and annually is the minimum monitoring standard. Hematocrit above 54% warrants dose reduction or phlebotomy. PSA should be checked at baseline and at 3 to 6 months [1].

Any man with a history of prostate cancer, breast cancer, hematocrit above 54% at baseline, or untreated severe obstructive sleep apnea is contraindicated for TRT under current Endocrine Society guidance [1].